{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:34:03Z","timestamp":1790393643851,"version":"4.1.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T00:00:00Z","timestamp":1666569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T00:00:00Z","timestamp":1666569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s11899-022-00684-2","type":"journal-article","created":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T07:03:38Z","timestamp":1666595018000},"page":"275-285","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Approach Toward Germline Predisposition Syndromes in Patients with Hematologic Malignancies"],"prefix":"10.1007","volume":"17","author":[{"given":"Himachandana","family":"Atluri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoheved S.","family":"Gerstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-0390","authenticated-orcid":false,"given":"Courtney D.","family":"DiNardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,24]]},"reference":[{"key":"684_CR1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544.","journal-title":"Blood"},{"key":"684_CR2","unstructured":"National Comprehensive Cancer Network\u00ae. (2022). Guideline: myelodysplastic syndromes. NCCN.\u00a0https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/mds.pdf. Accessed 15 Jul 2022."},{"key":"684_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.28092\/j.issn.2095-3941.2016.0004","volume":"13","author":"SP Strom","year":"2016","unstructured":"Strom SP. Current practices and guidelines for clinical next-generation sequencing oncology testing. Cancer Biol Med. 2016;13:3\u201311. https:\/\/doi.org\/10.28092\/j.issn.2095-3941.2016.0004.","journal-title":"Cancer Biol Med"},{"key":"684_CR4","doi-asserted-by":"publisher","unstructured":"Desai AV, Perpich M and Godley LA. Clinical assessment and diagnosis of germline predisposition to hematopoietic malignancies: the University of Chicago experience. Frontiers in Pediatrics 2017; 5. Review. https:\/\/doi.org\/10.3389\/fped.2017.00252.","DOI":"10.3389\/fped.2017.00252"},{"key":"684_CR5","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1002\/cncr.31331","volume":"124","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Routbort MJ, Bannon SA, et al. Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels. Cancer. 2018;124:2704\u201313. https:\/\/doi.org\/10.1002\/cncr.31331.","journal-title":"Cancer"},{"key":"684_CR6","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1016\/S2152-2650(20)30451-1","volume":"20","author":"C DiNardo","year":"2020","unstructured":"DiNardo C. Hereditary hematologic malignancies. Clin Lymphoma Myeloma Leuk. 2020;20:S27\u20139. https:\/\/doi.org\/10.1016\/S2152-2650(20)30451-1.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"684_CR7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41525-021-00198-5","volume":"6","author":"MLW Kam","year":"2021","unstructured":"Kam MLW, Nguyen TTT, Ngeow JYY. Telomere biology disorders. npj. Genomic Medicine. 2021;6:36. https:\/\/doi.org\/10.1038\/s41525-021-00198-5.","journal-title":"Genomic Medicine"},{"key":"684_CR8","doi-asserted-by":"publisher","unstructured":"Gutierrez-Rodrigues F, Groarke EM, Cl\u00e9 DV, et al. Clonal hematopoiesis in telomere biology disorders associates with the underlying germline defect and somatic mutations in POT1, PPM1D, and TERT promoter. Blood. 2021;138:1111\u20131111. https:\/\/doi.org\/10.1182\/blood-2021-151199. Accessed 5 Sept\u00a02022.","DOI":"10.1182\/blood-2021-151199"},{"key":"684_CR9","doi-asserted-by":"publisher","first-page":"232470962093894","DOI":"10.1177\/2324709620938941","volume":"8","author":"T Kewan","year":"2020","unstructured":"Kewan T, Noss R, Godley LA, et al. Inherited thrombocytopenia caused by germline ANKRD26 mutation should be considered in young patients with suspected myelodysplastic syndrome. J Investig Med High Impact Case Rep. 2020;8:2324709620938941\u20132324709620938941. https:\/\/doi.org\/10.1177\/2324709620938941.","journal-title":"J Investig Med High Impact Case Rep"},{"key":"684_CR10","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/ng.3177","volume":"47","author":"MY Zhang","year":"2015","unstructured":"Zhang MY, Churpek JE, Keel SB, et al. Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy. Nat Genet. 2015;47:180\u20135. https:\/\/doi.org\/10.1038\/ng.3177.","journal-title":"Nat Genet"},{"key":"684_CR11","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1182\/bloodadvances.2019000901","volume":"4","author":"AL Brown","year":"2020","unstructured":"Brown AL, Arts P, Carmichael CL, et al. RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML. Blood Adv. 2020;4:1131\u201344. https:\/\/doi.org\/10.1182\/bloodadvances.2019000901.","journal-title":"Blood Adv"},{"key":"684_CR12","doi-asserted-by":"publisher","first-page":"846","DOI":"10.3324\/haematol.2015.130799","volume":"101","author":"P Anand","year":"2016","unstructured":"Anand P, Katja S, Alexander P, et al. Whole exome sequencing reveals a C-terminal germline variant in CEBPA-associated acute myeloid leukemia: 45-year follow up of a large family. Haematologica. 2016;101:846\u201352. https:\/\/doi.org\/10.3324\/haematol.2015.130799.","journal-title":"Haematologica"},{"key":"684_CR13","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s13238-016-0351-9","volume":"8","author":"Y Jiang","year":"2017","unstructured":"Jiang Y, Zhu Y, Qiu W, et al. Structural and functional analyses of human DDX41 DEAD domain. Protein Cell. 2017;8:72\u20136. https:\/\/doi.org\/10.1007\/s13238-016-0351-9.","journal-title":"Protein Cell"},{"key":"684_CR14","doi-asserted-by":"publisher","first-page":"4780","DOI":"10.1182\/blood.V126.23.4780.4780","volume":"126","author":"BP Alter","year":"2015","unstructured":"Alter BP, Ballew BJ, Giri N, et al. Novel Fanci mutations in Fanconi anemia with Vacterl Association. Blood. 2015;126:4780\u20134780. https:\/\/doi.org\/10.1182\/blood.V126.23.4780.4780.","journal-title":"Blood"},{"key":"684_CR15","unstructured":"Fanconi Anemia Research Fund I. Fanconi anemia: guidelines for diagnosis and management. 5th ed. 2020. https:\/\/www.fanconi.org\/images\/uploads\/other\/Fanconi_Anemia_Clinical_Care_Guidelines_5thEdition_web.pdf."},{"key":"684_CR16","doi-asserted-by":"publisher","first-page":"100589","DOI":"10.1016\/j.blre.2019.100589","volume":"37","author":"MO Fiesco-Roa","year":"2019","unstructured":"Fiesco-Roa MO, Giri N, McReynolds LJ, et al. Genotype-phenotype associations in Fanconi anemia: a literature review. Blood Rev. 2019;37:100589\u2013100589. https:\/\/doi.org\/10.1016\/j.blre.2019.100589 (2019\/07\/16).","journal-title":"Blood Rev"},{"key":"684_CR17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1182\/blood-2020-137200","volume":"136","author":"B Altintas","year":"2020","unstructured":"Altintas B, Giri N, McReynolds LJ, et al. Genotype-Phenotype Associations in Patients with Fanconi Anemia: National Cancer Institute Cohort. Blood. 2020;136:4\u20135. https:\/\/doi.org\/10.1182\/blood-2020-137200.","journal-title":"Blood"},{"key":"684_CR18","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.clml.2016.04.001","volume":"16","author":"CD DiNardo","year":"2016","unstructured":"DiNardo CD, Bannon SA, Routbort M, et al. Evaluation of patients and families with concern for predispositions to hematologic malignancies within the hereditary hematologic malignancy clinic (HHMC). Clin Lymphoma Myeloma Leuk. 2016;16:417\u201328. https:\/\/doi.org\/10.1016\/j.clml.2016.04.001 (e412. 2016\/05\/24).","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"684_CR19","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cll.2021.04.014","volume":"41","author":"MT Elghetany","year":"2021","unstructured":"Elghetany MT, Punia JN, Marcogliese AN. Inherited bone marrow failure Syndromes: Biology and Diagnostic Clues. Clin Lab Med. 2021;41:417\u201331. https:\/\/doi.org\/10.1016\/j.cll.2021.04.014.","journal-title":"Clin Lab Med"},{"key":"684_CR20","doi-asserted-by":"publisher","first-page":"4584","DOI":"10.1182\/bloodadvances.2020002953","volume":"4","author":"EH Bresnick","year":"2020","unstructured":"Bresnick EH, Jung MM, Katsumura KR. Human GATA2 mutations and hematologic disease: how many paths to pathogenesis? Blood Adv. 2020;4:4584\u201392. https:\/\/doi.org\/10.1182\/bloodadvances.2020002953.","journal-title":"Blood Adv"},{"key":"684_CR21","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1182\/blood-2015-09-669937","volume":"127","author":"MW Wlodarski","year":"2016","unstructured":"Wlodarski MW, Hirabayashi S, Pastor V, et al. Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents. Blood. 2016;127:1387\u201397. https:\/\/doi.org\/10.1182\/blood-2015-09-669937.","journal-title":"Blood"},{"key":"684_CR22","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1182\/blood-2018-07-861070","volume":"132","author":"P Galera","year":"2018","unstructured":"Galera P, Hsu AP, Wang W, et al. Donor-derived MDS\/AML in families with germline GATA2 mutation. Blood. 2018;132:1994\u20138. https:\/\/doi.org\/10.1182\/blood-2018-07-861070.","journal-title":"Blood"},{"key":"684_CR23","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/ng.923","volume":"43","author":"P Ostergaard","year":"2011","unstructured":"Ostergaard P, Simpson MA, Connell FC, et al. Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome). Nat Genet. 2011;43:929\u201331. https:\/\/doi.org\/10.1038\/ng.923.","journal-title":"Nat Genet"},{"key":"684_CR24","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1182\/blood-2011-05-356352","volume":"118","author":"AP Hsu","year":"2011","unstructured":"Hsu AP, Sampaio EP, Khan J, et al. Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood. 2011;118:2653\u20135. https:\/\/doi.org\/10.1182\/blood-2011-05-356352.","journal-title":"Blood"},{"key":"684_CR25","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1038\/s41375-018-0074-4","volume":"32","author":"J Davidsson","year":"2018","unstructured":"Davidsson J, Puschmann A, Tedg\u00e5rd U, et al. SAMD9 and SAMD9L in inherited predisposition to ataxia, pancytopenia, and myeloid malignancies. Leukemia. 2018;32:1106\u201315. https:\/\/doi.org\/10.1038\/s41375-018-0074-4.","journal-title":"Leukemia"},{"key":"684_CR26","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1038\/s41375-021-01212-6","volume":"35","author":"ME Thomas","year":"2021","unstructured":"Thomas ME, Abdelhamed S, Hiltenbrand R, et al. Pediatric MDS and bone marrow failure-associated germline mutations in SAMD9 and SAMD9L impair multiple pathways in primary hematopoietic cells. Leukemia. 2021;35:3232\u201344. https:\/\/doi.org\/10.1038\/s41375-021-01212-6.","journal-title":"Leukemia"},{"key":"684_CR27","doi-asserted-by":"publisher","unstructured":"Schwartz JR, Wlodarski MW and Klco JM. Role of genetic evolution and germline mutations in SAMD9 and SAMD9L genes. Blood 2019; 134: SCI-33-SCI-33. https:\/\/doi.org\/10.1182\/blood-2019-121042.","DOI":"10.1182\/blood-2019-121042"},{"key":"684_CR28","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.hoc.2012.10.004","volume":"27","author":"MS Horwitz","year":"2013","unstructured":"Horwitz MS, Corey SJ, Grimes HL, et al. ELANE mutations in cyclic and severe congenital neutropenia: genetics and pathophysiology. Hematol Oncol Clin North Am. 2013;27:19\u2013vii. https:\/\/doi.org\/10.1016\/j.hoc.2012.10.004 (2012\/11\/07).","journal-title":"Hematol Oncol Clin North Am"},{"key":"684_CR29","doi-asserted-by":"publisher","unstructured":"Rydzynska Z, Pawlik B, Krzyzanowski D, et al. Neutrophil elastase defects in congenital neutropenia. Frontiers in Immunology 2021; 12. Review. https:\/\/doi.org\/10.3389\/fimmu.2021.653932.","DOI":"10.3389\/fimmu.2021.653932"},{"key":"684_CR30","doi-asserted-by":"publisher","unstructured":"Baptista RLR, dos Santos ACE, Gutiyama LM, et al. Familial myelodysplastic\/acute leukemia syndromes\u2014myeloid neoplasms with germline predisposition. Frontiers in Oncology 2017; 7. Review. https:\/\/doi.org\/10.3389\/fonc.2017.00206.","DOI":"10.3389\/fonc.2017.00206"},{"key":"684_CR31","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.3324\/haematol.2017.167726","volume":"102","author":"K-S Rashmi","year":"2017","unstructured":"Rashmi K-S, Sanam L, Courtney DD, et al. Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation. Haematologica. 2017;102:1661\u201370. https:\/\/doi.org\/10.3324\/haematol.2017.167726.","journal-title":"Haematologica"},{"key":"684_CR32","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1056\/NEJMoa041331","volume":"351","author":"ML Smith","year":"2004","unstructured":"Smith ML, Cavenagh JD, Lister TA, et al. Mutation of CEBPA in familial acute myeloid leukemia. N Engl J Med. 2004;351:2403\u20137. https:\/\/doi.org\/10.1056\/NEJMoa041331.","journal-title":"N Engl J Med"},{"key":"684_CR33","doi-asserted-by":"publisher","first-page":"24970","DOI":"10.18632\/oncotarget.23873","volume":"9","author":"L Su","year":"2018","unstructured":"Su L, Tan Y, Lin H, et al. Mutational spectrum of acute myeloid leukemia patients with double CEBPA mutations based on next-generation sequencing and its prognostic significance. Oncotarget. 2018;9:24970\u20139. https:\/\/doi.org\/10.18632\/oncotarget.23873.","journal-title":"Oncotarget"},{"key":"684_CR34","doi-asserted-by":"publisher","first-page":"9114","DOI":"10.4081\/hr.2021.9114","volume":"13","author":"M Boada","year":"2021","unstructured":"Boada M, Catal\u00e1n AI, Ottati C, et al. Germline CEBPA mutation in familial acute myeloid leukemia. Hematol Rep. 2021;13:9114\u20139114. https:\/\/doi.org\/10.4081\/hr.2021.9114.","journal-title":"Hematol Rep"},{"key":"684_CR35","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1182\/blood-2015-05-647172","volume":"126","author":"K Tawana","year":"2015","unstructured":"Tawana K, Wang J, Renneville A, et al. Disease evolution and outcomes in familial AML with germline CEBPA mutations. Blood. 2015;126:1214\u201323. https:\/\/doi.org\/10.1182\/blood-2015-05-647172.","journal-title":"Blood"},{"key":"684_CR36","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1182\/blood-2015-07-657908","volume":"126","author":"CD DiNardo","year":"2015","unstructured":"DiNardo CD. Getting a handle on hereditary CEBPA mutations. Blood. 2015;126:1156\u20138. https:\/\/doi.org\/10.1182\/blood-2015-07-657908.","journal-title":"Blood"},{"key":"684_CR37","unstructured":"Churpek JE and Smith-Simmer K. DDX41-Associated familial myelodysplastic syndrome and acute myeloid leukemia. In: Adam MP, Ardinger HH, Pagon RA, et al. (eds) GeneReviews(\u00ae). Seattle (WA): University of Washington, Seattle. Copyright \u00a9 1993\u20132022, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved., 1993."},{"key":"684_CR38","doi-asserted-by":"publisher","unstructured":"Bannon SA, Routbort MJ, Montalban-Bravo G, et al. Next-generation sequencing of DDX41 in myeloid neoplasms leads to increased detection of germline alterations. Frontiers in Oncology 2021; 10. Original Research. https:\/\/doi.org\/10.3389\/fonc.2020.582213.","DOI":"10.3389\/fonc.2020.582213"},{"key":"684_CR39","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/s41375-021-01404-0","volume":"36","author":"P Li","year":"2022","unstructured":"Li P, White T, Xie W, et al. AML with germline DDX41 variants is a clinicopathologically distinct entity with an indolent clinical course and favorable outcome. Leukemia. 2022;36:664\u201374. https:\/\/doi.org\/10.1038\/s41375-021-01404-0.","journal-title":"Leukemia"},{"key":"684_CR40","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1182\/blood.2019000909","volume":"134","author":"M S\u00e9bert","year":"2019","unstructured":"S\u00e9bert M, Passet M, Raimbault A, et al. Germline DDX41 mutations define a significant entity within adult MDS\/AML patients. Blood. 2019;134:1441\u20134. https:\/\/doi.org\/10.1182\/blood.2019000909.","journal-title":"Blood"},{"key":"684_CR41","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jama.2018.13152","volume":"320","author":"J Mersch","year":"2018","unstructured":"Mersch J, Brown N, Pirzadeh-Miller S, et al. Prevalence of variant reclassification following hereditary cancer genetic testing. JAMA. 2018;320:1266\u201374. https:\/\/doi.org\/10.1001\/jama.2018.13152.","journal-title":"JAMA"},{"key":"684_CR42","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13073-019-0688-9","volume":"11","author":"SM Harrison","year":"2019","unstructured":"Harrison SM, Rehm HL. Is \u2018likely pathogenic\u2019 really 90% likely? Reclassification data in ClinVar. Genome Medicine. 2019;11:72. https:\/\/doi.org\/10.1186\/s13073-019-0688-9.","journal-title":"Genome Medicine"},{"key":"684_CR43","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41408-018-0148-6","volume":"8","author":"U Bacher","year":"2018","unstructured":"Bacher U, Shumilov E, Flach J, et al. Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use. Blood Cancer J. 2018;8:113. https:\/\/doi.org\/10.1038\/s41408-018-0148-6.","journal-title":"Blood Cancer J"},{"key":"684_CR44","doi-asserted-by":"publisher","unstructured":"Abou Dalle I, Bannon SA, Patel KP, et al. Germline genetic predisposition to myeloid neoplasia from GATA2 gene mutations: lessons learned from two cases. JCO precision oncology 2019; 3: PO.18.00301. https:\/\/doi.org\/10.1200\/PO.18.00301.","DOI":"10.1200\/PO.18.00301"},{"key":"684_CR45","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1200\/jco.2016.70.8644","volume":"35","author":"E Furutani","year":"2017","unstructured":"Furutani E, Shimamura A. Germline genetic predisposition to hematologic malignancy. J Clin Oncol. 2017;35:1018\u201328. https:\/\/doi.org\/10.1200\/jco.2016.70.8644.","journal-title":"J Clin Oncol"},{"key":"684_CR46","doi-asserted-by":"publisher","unstructured":"Donovan LN, Kohlmann W, Snow AK, et al. Germ cell mosaicism: a rare cause of Li-Fraumeni recurrence among siblings. JCO Precision Oncology 2020: 662\u2013664. https:\/\/doi.org\/10.1200\/po.20.00064.","DOI":"10.1200\/po.20.00064"},{"key":"684_CR47","doi-asserted-by":"publisher","first-page":"4157","DOI":"10.1182\/blood-2009-11-203182","volume":"115","author":"S Heinrichs","year":"2010","unstructured":"Heinrichs S, Li C, Look AT. SNP array analysis in hematologic malignancies: avoiding false discoveries. Blood. 2010;115:4157\u201361. https:\/\/doi.org\/10.1182\/blood-2009-11-203182.","journal-title":"Blood"},{"key":"684_CR48","doi-asserted-by":"publisher","unstructured":"Roloff GW, Drazer MW and Godley LA. Inherited susceptibility to hematopoietic malignancies in the era of precision oncology. JCO Precision Oncology 2021: 107\u2013122. https:\/\/doi.org\/10.1200\/po.20.00387.","DOI":"10.1200\/po.20.00387"},{"key":"684_CR49","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1182\/hematology.2020006910","volume":"2020","author":"IL Kraft","year":"2020","unstructured":"Kraft IL, Godley LA. Identifying potential germline variants from sequencing hematopoietic malignancies. Hematology. 2020;2020:219\u201327. https:\/\/doi.org\/10.1182\/hematology.2020006910.","journal-title":"Hematology"},{"key":"684_CR50","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1182\/blood-2020-138431","volume":"136","author":"L DeRoin","year":"2020","unstructured":"DeRoin L, De Andrade Cavalcante, Silva M, Petras K, et al. Assessing the feasibility and limitations of cultured skin fibroblasts for germline genetic testing in hematologic disorders. Blood. 2020;136:35\u20136. https:\/\/doi.org\/10.1182\/blood-2020-138431.","journal-title":"Blood"},{"key":"684_CR51","doi-asserted-by":"publisher","unstructured":"DeRoin L, de Andrade Cavalcante, Silva M, Petras K, et al. Feasibility and limitations of cultured skin fibroblasts for germline genetic testing in hematologic disorders. Human Mutation. 2022;43:950\u201362. https:\/\/doi.org\/10.1002\/humu.24374. Accessed 5 Sept 2022.","DOI":"10.1002\/humu.24374"},{"key":"684_CR52","doi-asserted-by":"publisher","first-page":"8.7.1","DOI":"10.1002\/0471142905.hg0807s85","volume":"85","author":"AD Auerbach","year":"2015","unstructured":"Auerbach AD. Diagnosis of Fanconi anemia by diepoxybutane analysis. Curr Protoc Hum Genet. 2015;85:8.7.1-8.7.17. https:\/\/doi.org\/10.1002\/0471142905.hg0807s85.","journal-title":"Curr Protoc Hum Genet"},{"key":"684_CR53","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1182\/blood-2017-01-734558","volume":"130","author":"JM Marron","year":"2017","unstructured":"Marron JM, Joffe S. Ethical considerations in genomic testing for hematologic disorders. Blood. 2017;130:460\u20135. https:\/\/doi.org\/10.1182\/blood-2017-01-734558.","journal-title":"Blood"},{"key":"684_CR54","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2017-02-735290","volume":"130","author":"LA Godley","year":"2017","unstructured":"Godley LA, Shimamura A. Genetic predisposition to hematologic malignancies: management and surveillance. Blood. 2017;130:424\u201332. https:\/\/doi.org\/10.1182\/blood-2017-02-735290.","journal-title":"Blood"},{"key":"684_CR55","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/j.1365-2141.2008.07269.x","volume":"142","author":"A Vlachos","year":"2008","unstructured":"Vlachos A, Ball S, Dahl N, et al. Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference. Br J Haematol. 2008;142:859\u201376. https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07269.x.","journal-title":"Br J Haematol"},{"key":"684_CR56","doi-asserted-by":"publisher","first-page":"3715","DOI":"10.1182\/blood-2010-02-251090","volume":"116","author":"A Vlachos","year":"2010","unstructured":"Vlachos A, Muir E. How I treat Diamond-Blackfan anemia. Blood. 2010;116:3715\u201323. https:\/\/doi.org\/10.1182\/blood-2010-02-251090.","journal-title":"Blood"},{"key":"684_CR57","doi-asserted-by":"crossref","unstructured":"Dyskeratosis congenita and telomere biology disorders: diagnosis and management guidelines. 2nd ed. 2022. https:\/\/teamtelomere.org\/wp-content\/uploads\/2022\/04\/Telomere-Biology-Disorders_-Diagnosis-and-Management-Guidelines.pdf","DOI":"10.1182\/hematology.2022000394"},{"key":"684_CR58","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/bmt.2008.151","volume":"42","author":"D Bhatla","year":"2008","unstructured":"Bhatla D, Davies SM, Shenoy S, et al. Reduced-intensity conditioning is effective and safe for transplantation of patients with Shwachman-Diamond syndrome. Bone Marrow Transplant. 2008;42:159\u201365. https:\/\/doi.org\/10.1038\/bmt.2008.151.","journal-title":"Bone Marrow Transplant"},{"key":"684_CR59","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/bmt.2015.117","volume":"50","author":"R Peffault de Latour","year":"2015","unstructured":"Peffault de Latour R, Peters C, Gibson B, et al. Recommendations on hematopoietic stem cell transplantation for inherited bone marrow failure syndromes. Bone Marrow Transplantation. 2015;50:1168\u201372. https:\/\/doi.org\/10.1038\/bmt.2015.117.","journal-title":"Bone Marrow Transplantation"},{"key":"684_CR60","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1182\/hematology.2020000095","volume":"2020","author":"C Bonfim","year":"2020","unstructured":"Bonfim C. Special pre- and posttransplant considerations in inherited bone marrow failure and hematopoietic malignancy predisposition syndromes. Hematology. 2020;2020:107\u201314. https:\/\/doi.org\/10.1182\/hematology.2020000095.","journal-title":"Hematology"},{"key":"684_CR61","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1182\/bloodadvances.2019001210","volume":"4","author":"B Strahm","year":"2020","unstructured":"Strahm B, Loewecke F, Niemeyer CM, et al. Favorable outcomes of hematopoietic stem cell transplantation in children and adolescents with Diamond-Blackfan anemia. Blood Adv. 2020;4:1760\u20139. https:\/\/doi.org\/10.1182\/bloodadvances.2019001210.","journal-title":"Blood Adv"},{"key":"684_CR62","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.bbmt.2016.03.007","volume":"22","author":"C Bonfim","year":"2016","unstructured":"Bonfim C, Ribeiro L, Nichele S, et al. Long-term survival, organ function, and malignancy after hematopoietic stem cell transplantation for Fanconi anemia. Biol Blood Marrow Transplant. 2016;22:1257\u201363. https:\/\/doi.org\/10.1016\/j.bbmt.2016.03.007.","journal-title":"Biol Blood Marrow Transplant"},{"key":"684_CR63","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.bbmt.2017.05.022","volume":"23","author":"AC Dietz","year":"2017","unstructured":"Dietz AC, Savage SA, Vlachos A, et al. Late effects screening guidelines after hematopoietic cell transplantation for inherited bone marrow failure syndromes consensus statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects After Pediatric HCT. Biol Blood Marrow Transplant. 2017;23:1422\u20138. https:\/\/doi.org\/10.1016\/j.bbmt.2017.05.022 (2017\/05\/19).","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-022-00684-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-022-00684-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-022-00684-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T18:47:08Z","timestamp":1678387628000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-022-00684-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,24]]},"references-count":63,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["684"],"URL":"https:\/\/doi.org\/10.1007\/s11899-022-00684-2","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,24]]},"assertion":[{"value":"24 September 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare the following potential conflicts of interest for the research, authorship, and\/or publication of this article. Himachandana Atluri and Yoheved S. Gerstein have no relevant financial or non-financial interests to disclose. Courtney D. DiNardo has received research funding from Abbvie, Agios\/Servier, Astex, Calithera, Celgene\/BMS, Cleave, Foghorn, ImmuneOnc, and Loxo. She has also received honoraria\/consulting fees from Abbvie, Agios\/Servier, Astellas, Celgene\/BMS, Cleave, Foghorn, Genentech, GenMab, GSK, Novartis, Notable Labs, and Takeda.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent."}}]}}